Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2403-2406

  Schirrmacher, Volker ^a,b   Bihari, Akos Sigmund ^a   Stücker, Wilfried ^a   Sprenger, Tobias ^a  

^a Immunological Oncological Center   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Dendritic cell vaccination; Hyperthermia; Immunotherapy; Newcastle disease virus; Prostate cancer

Indexed keywords

BICALUTAMIDE; GAMMA INTERFERON; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 4; KETOCONAZOLE; LEUPRORELIN; OCTREOTIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; EVENING DOSAGE; GLEASON SCORE; HUMAN; HYPERTHERMIA; MALE; MORNING DOSAGE; OUTCOME ASSESSMENT; PELVIS LYMPHADENECTOMY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; SCINTIGRAPHY; TUMOR REGRESSION; VIROTHERAPY;

EID: 84908022126     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2588     Document Type: Article

References (16)

1. Robert-Koch Institut. The Federal Health Monitoring-Prostate Diseases. Robert Kock-Institut, Berlin, pp36, 2007.
2. Eisenberg DP, Carpenter SG, Adusumilli PS, Chan MK, Hendershott KJ, Yu Z and Fong Y: Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway. Surgery 148: 325-334, 2010.
3. Dendreon Press Release: FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer. http:// http://investor.dendreon.com/releasedetail.cfm?ReleaseID=533434. Accessed August 7, 2013
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW and Schellhammer PF; IMPACT study investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010.
5. Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A and von Bergwelt-Baildon M: Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 6: e18801, 2011.
6. Fournier P, Bian H, Szeberényi J and Schirrmacher V: Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Methods Mol Biol 797: 177-204, 2012.
7. Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R and Riess H: The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43: 33-56, 2002.
8. Rao W, Deng ZS and Liu J: A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng 38: 101-116, 2010.
9. Schirrmacher V, Fournier P and Schlag P: Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines 13: 117-130, 2014.
10. Gulley JL, Madan RA and Schlom J: Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol 18: e150-e157, 2011.
11. Wilt TJ, Brawer MK, Jones KM, et al: Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367: 203-213, 2012.
12. Chang E, Chalikonda S, Friedl J, Xu H, Phan GQ, Marincola FM, Alexander HR and Bartlett DL: Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 16: 435-444, 2005.
13. Workenhe ST and Mossman KL: Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther 22: 251-256, 2014.
14. Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R, Lotze MT and Tang D: Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis 4: e966, 2013.
15. Knippertz I, Stein MF, Dörrie J, Schaft N, Müller I, Deinzer A, Steinkasserer A and Nettelbeck DM: Mild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies. Int J Hyperthermia 27: 591-603, 2011.
16. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H and Riley D; CARE Group: The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol 67: 46-51, 2014.